Select Bibliography

Filter by any of these (after searching):

Anderson, S. Keith

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 30 items

Validating RNAseq-Signatures of Vorinostat (VOR) Sensitivity and Resistance in Patients with Newly Diagnosed Glioblastoma (GBM) Treated with VOR, Temozolomide and Radiation Therapy From Alliance N0874/ABTC-0902.

Anderson, S. Keith , Miller, C. Ryan , Sarkaria, Jann N. ... - ASCO - J Clin Oncol - 2016

Abstract - Secondary - Primary - Neuro-Onc - N0874 , ABTC-0902

Alliance A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) Vaccine Given with Bevacizumab versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma

Bloch, Orin , Shi, Qian , Anderson, S. Keith , Knopp, Michael ... - SNO - Neuro-oncology - 2017

Abstract - Primary - Primary - Neuro-Onc - A071101

Long term outcomes from intergroup NCCTG 86-72-51 (Alliance): Final report of a phase III prospective randomized trial of high dose versus low dose radiation therapy in adults with supratentorial low-grade glioma.

Breen, William G. , Anderson, S. Keith , Carrero, Xiomara W ... - SNO - Neuro-oncology - 2019

Abstract - Primary - Long-Term-Followup - Neuro-Onc - NCCTG-85-72-51

Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance)

Brown, Paul D. , Anderson, S. Keith , Carrero, Xiomara W. ... - - Neurooncol Pract - 2015

Manuscript - Primary - Long-Term-Followup - Neuro-Onc - NCCTG-86-72-51

NCCTG N0574 (Alliance): A Phase III Randomized Trial of Whole Brain Radiation Therapy (WBRT) in Addition to Radiosurgery (SRS) in Patients with 1 to 3 Brain Metastases.

Brown, Paul D. , Asher, Anthony L. , Ballman, Karla V. ... - SNO - Neuro Oncol - 2015

Abstract - Primary - Primary - Neuro-Onc - N0574

NCCTG N0574 (Alliance): A Phase III Randomized Trial of Whole Brain Radiation Therapy (WBRT) in Addition to Radiosurgery (SRS) in Patients with 1 to 3 Brain Metastases

Brown, Paul D. , Asher, Anthony L. , Ballman, Karla V. ... - ASCO - J Clin Oncol - 2015

Abstract - Primary - Primary - Neuro-Onc - N0574

N107C/CEC.3 (Alliance/NCIC): Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease

Brown, Paul D. , Ballman, Karla V. , Cerhan, Jane H. ... - ASTRO - Int J Radiat Oncol Biol Phys - 2016

Abstract - Primary - Primary - Neuro-Onc - N107C

Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases

Brown, Paul D. , Jaeckle, Kurt , Ballman, Karla V. , Farace, Elana ... - - JAMA - 2016

Manuscript - Primary - Primary - Neuro-Onc - N0574

Stereotactic Radiosurgery with or without Whole Brain Radiotherapy for Limited Brain Metastases: A Secondary Analysis of the NCCTG N0574 (Alliance) Randomized Controlled Trial

Churilla, Thomas M. , Ballman, Karla V. , Brown, Paul D. ... - - Int J Radiat Oncol Biol Phys - 2017

Manuscript - Secondary - Primary - Neuro-Onc - N0574

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study

Friday, Bret B. , Anderson, S. Keith , Buckner, Jan , Yu, Chunrong ... - - Neuro Oncol - 2012

Manuscript - Primary - Primary - Neuro-Onc - N0779

NCCTG N0872 (Alliance): A Randomized Placebo-Controlled Phase II Trial of Bevacizumab Plus Dasatinib in Patients with Recurrent Glioblastoma (GBM)

Galanis, Evanthia , Anderson, S. Keith , Anastasiadis, Panagiotis Z. ... - ASCO - J Clin Oncol - 2015

Abstract - Primary - Primary - Neuro-Onc - N0872

NCCTG N1174: Phase I/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme (Alliance)

Galanis, Evanthia , Anderson, S. Keith , Butowski, Nicholas ... - ASCO - J Clin Oncol - 2017

Abstract - Primary - Primary - Neuro-Onc - N1174

Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902)

Galanis, Evanthia , Anderson, S. Keith , Miller, C. Ryan ... - ASCO - J Clin Oncol - 2014

Abstract - Primary - Primary - Neuro-Onc - N0874

A Phase I and Randomized Placebo-Controlled Phase II Trial of Bevacizumab plus Dasatinib in Patients with Recurrent Glioblastoma (GBM): Alliance/NCCTG N0872

Galanis, Evanthia , Anderson, S. Keith , Twohy, Erin L. ... - - Cancer - 2019

Manuscript - Primary - Primary - Neuro-Onc - N0872

Local control after resection and adjuvant radiosurgery compared to radiosurgery alone for brain metastasis: Exploratory analysis of Alliance NCCTG N107C

Hansen, Chase C. , Ballman, Karla V. , Anderson, S. Keith ... - ASTRO - Int J Radiation Biol Physics - 2020

Abstract - Secondary-not-in-original - Primary - Neuro-Onc - N107C

CODEL: Phase III study of RT alone, RT plus temozolomide, or temozolomide alone for newly diagnosed 1P/19Q codeleted anaplastic oligodendroglioma patients. Updated analysis from the initial study design (NCCTG N0577, Alliance)

Jaeckle, Kurt A. , Ballman, Karla V. , van den Bent, Martin ... - SNO - Neuro-oncology - 2020

Abstract - Primary - Other - Neuro-Onc - N0577

CODEL (Alliance-N0577; EORTC-26081/22086; NRG-1071; NCIC-CEC-2): Phase III randomized study of RT vs. RT+TMZ vs. TMZ for newly diagnosed 1p/19q-codeleted anaplastic glioma. Analysis of patients treated on the original protocol design

Jaeckle, Kurt , Vogelbaum, Michael , Ballman, Karla ... - AAN - Neurology - 2016

Abstract - Primary - Other - Neuro-Onc - N0577

Randomized Placebo-Controlled Phase II Study of Dasatinib with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma (GBM), N0877

Laack, Nadia , Galanis, Eva , Anderson, S. Keith , Leinweber, Clinton ... - ASCO - J Clin Oncol - 2015

Abstract - Primary - Primary - Neuro-Onc - N0877

A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K

Ma, Daniel J. , Galanis, Evanthia , Anderson, S. Keith ... - - Neuro-oncology - 2015

Manuscript - Primary - Long-Term-Followup - Neuro-Onc - N057K

Association of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Brain Metastasis

Palmer, Joshua D. , Klamer, Brett G. , Ballman, Karla V. ... - - JAMA Oncol - 2022

Manuscript - Secondary-not-in-original - Primary - Neuro-Onc - N107C

Effect of stereotactic radiosurgery compared to whole-brain radiotherapy for limited brain metastasis on long term cognition and quality of life: A pooled analysis of N107C/CEC.3 and N0574 randomized clinical trials (Alliance)

Palmer, Joshua D. , Klamer, Brett G. , Ballman, Karla V. ... - ASTRO - Int J Radiation Biol Physics - 2020

Abstract - Secondary-not-in-original - Meta-Analysis - Health Outcomes - N0574 , N107C

Stromal tumor infiltrating lymphocytes: In the Alliance N9831 trial STILS are prognostic of chemotherapy benefit but not predictive of trastuzumab benefit

Perez, Edith A. , Ballman, Karla V. , Anderson, S. Keith ... - SABCS - Cancer Res - 2015

Abstract - Secondary-not-in-original - Primary - Breast - N9831

C-MYC Alterations and Association With Patient Outcome in Early-Stage HER2-Positive Breast Cancer From the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial

Perez, Edith A. , Jenkins, Robert B. , Dueck, Amylou C. ... - - J Clin Oncol - 2011

Manuscript - Secondary - Primary - Breast - N9831

Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.

Perez, Edith A. , Thompson, E. Aubrey , Anderson, S. Keith ... - ASCO - J Clin Oncol - 2014

Abstract - Secondary-not-in-original - Primary - Breast - N9831

Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial

Perez, Edith A. , Thompson, E. Aubrey , Ballman, Karla V. ... - - J Clin Oncol - 2015

Manuscript - Secondary - Primary - Breast - N9831

Quality of Life Analysis of N0877 (Alliance): Phase II Trial of Either Dasatinib or Placebo Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM)

Qin, Rui , Tan, Angelina D. , Sloan, Jeff A. , Johnson, Derek Richard ... - ASCO - J Clin Oncol - 2015

Abstract - Secondary - Primary - Health Outcomes - N0877

N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group): Phase III Trial of Post-Operative Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease: Cognitive function of long-term survivors

Roberge, David , Ballman, Karla V. , Cerhan, Jane H. ... - SNO - Neuro-oncology - 2017

Abstract - Secondary - Primary - Neuro-Onc - N107C

Randomized Phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) with MGMT promoter hypermethylation

Sarkaria, Jann N. , Ballman, Karla V. , Kizilbash, Sani H. ... - ASCO - J Clin Oncol - 2022

Abstract - Primary - Primary - Neuro-Onc - A071102

Phase I/II Trial of Temsirolimus and Sorafenib in Treatment of Patients with Recurrent Glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572

Schiff, David , Jaeckle, Kurt A , Anderson, S. Keith ... - - Cancer - 2018

Manuscript - Primary - Primary - Neuro-Onc - N0572

Optimizing whole brain radiotherapy dose and fractionation: Results from a prospective phase III trial (Alliance)

Trifiletti, Daniel M. , Ballman, Karla V. , Brown, Paul D. ... - ASTRO - International Journal of Radiation Oncology • Biology • Physics - 2019

Abstract - Secondary-not-in-original - Primary - Neuro-Onc - N107C